It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with Multiple Myeloma

Clinical Trial Title: 
Pomalidomide/dexamethasone with or without elotuzumab for patients with multiple myeloma.
Clinical Trial Protocol ID: 
15120903
Clinical Trial Investigator Name: 
Agne Paner, MD
Clinical Trial Protocol Description: 

To provide pomalidomide/dexamethasone and/or elotuzumab treatment for patients with relapsed and refractory multiple myeloma and to collect additional data on treatment safety.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have ≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of lenalidomide and a proteosome inhibitor alone or in combination.
  • Have a refractory that progressed on or within 60 days of their last treatment.
  • Have a refractory to proteosome inhibitor and lenalidomide, and to last treatment.
  • Are a relapsed and/or refractory patient who has achieved at least a partial response to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months, and were refractory to their last treatment.
  • Have measurable disease at screening.
  • Are at least 18 years of age with ECOG performance status 0-2.

You will be excluded from the study if any of the following criteria apply to you:

  • Have active plasma cell leukemia.
  • Have solitary bone or extramedullary plasmacytoma as only evidence of plasma cell dyscrasia.
  • Have prior exposure to pomalidomide.
  • Have prior autologous stem cell transplant within 12 weeks.
  • Have prior allogeneic stem cell transplant within 12 months. (No history of GVHD and are not receiving topical or systemic immunosuppressive therapy.)
  • Are HIV positive or have active hepatitis A, B or C.
  • Have uncontrolled or severe cardiovascular or pulmonary disease or active infection requiring parenteral anti-infective treatment >14 days.
  • Have had major cardiac surgery within 8 weeks prior to study drug or other major surgery within 4 weeks.
  • Have undergone treatment with melphalan or monoclonal antibodies within 6 weeks of first dose of study drug or treatment.
  • Have undergone treatment with corticosteroids within 3 weeks of the first dose of study drug (except equivalent of < 10mg prednisone/day or steroids with minimal systemic absorption or for short course (< 4 days) of 40mg dexamethasone for emergency use.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-4685
Contact Name: 
Christine Deskovich RN, BSN, OCN